68
Views
13
CrossRef citations to date
0
Altmetric
Review

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

Pages 307-316 | Published online: 03 Oct 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ahmed Kamal, Thokhir Basha Shaik & Mohammed Shaheer Malik. (2015) Embracing synthetic lethality of novel anticancer therapies. Expert Opinion on Drug Discovery 10:10, pages 1119-1132.
Read now

Articles from other publishers (12)

I Nyoman Bayu Mahendra & William Alexander Setiawan. (2022) PARP Inhibitor for Ovarian Cancer Therapy. European Journal of Medical and Health Sciences 4:6, pages 1-7.
Crossref
Thalita Basso Scandolara, Bruno Ricardo Barreto Pires, Beatriz Vacario, Isis Salviano Soares de Amorim, Priscyanne Barreto Siqueira, Juliana Mara Serpeloni, André Luiz Mencalha, Cibele Rodrigues Bonvicino & Carolina Panis. (2022) An Overview Regarding Pharmacogenomics and Biomarkers Discovery: Focus on Breast Cancer. Current Topics in Medicinal Chemistry 22:20, pages 1654-1673.
Crossref
Marina K. Ibragimova, Matvey M. Tsyganov & Nikolai V. Litviakov. (2021) Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype. Cancers 13:21, pages 5348.
Crossref
Sevide Sencan, Mine Tanriover, Mustafa Ulasli, Didem Karakas & Bulent Ozpolat. (2021) UV radiation resistance-associated gene (UVRAG) promotes cell proliferation, migration, invasion by regulating cyclin-dependent kinases (CDK) and integrin-β/Src signaling in breast cancer cells. Molecular and Cellular Biochemistry 476:5, pages 2075-2084.
Crossref
Vikram Thakur & Rajaletchumy Veloo Kutty. (2019) Recent advances in nanotheranostics for triple negative breast cancer treatment. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Soley Bayraktar & Adnan Aydiner. 2019. Breast Cancer. Breast Cancer 483 508 .
Gamze Guney Eskiler, Gulsah Cecener, Unal Egeli & Berrin Tunca. (2018) Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer. Pharmaceutical Research 35:11.
Crossref
Ana C. Gregório, Manuela Lacerda, Paulo Figueiredo, Sérgio Simões, Sérgio Dias & João Nuno Moreira. (2017) Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathology & Oncology Research 24:4, pages 701-716.
Crossref
Bàrbara Roig, Marta Rodríguez-Balada, Sara Samino, Eric W.-F. Lam, Sandra Guaita-Esteruelas, Ana R. Gomes, Xavier Correig, Joan Borràs, Oscar Yanes & Josep Gumà. (2017) Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer. Scientific Reports 7:1.
Crossref
Henri Wathieu, Naiem T. Issa, Aileen I. Fernandez, Manisha Mohandoss, Deanna M. Tiek, Jennifer L. Franke, Stephen W. Byers, Rebecca B. Riggins & Sivanesan Dakshanamurthy. (2017) Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method. Oncotarget 8:54, pages 92926-92942.
Crossref
Davide Caruso, Anselmo Papa, Silverio Tomao, Patrizia Vici, Pierluigi Benedetti Panici & Federica Tomao. (2017) Niraparib in ovarian cancer: results to date and clinical potential. Therapeutic Advances in Medical Oncology 9:9, pages 579-588.
Crossref
Kyung-Hee Chun, Jong Hoon Park & Siting Fan. 2017. Translational Research in Breast Cancer. Translational Research in Breast Cancer 59 104 .